Analysts Set Hikma Pharmaceuticals PLC (LON:HIK) Price Target at GBX 1,687

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have been assigned a consensus rating of “Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have covered the stock in the last year is GBX 1,687.

HIK has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 195 price target on shares of Hikma Pharmaceuticals in a research note on Monday, June 22nd. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. Jefferies Financial Group upped their target price on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, Berenberg Bank reiterated a “buy” rating and issued a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th.

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock opened at GBX 1,549.46 on Thursday. The firm has a market capitalization of £3.26 billion, a price-to-earnings ratio of 8.56, a PEG ratio of 2.38 and a beta of 0.65. The stock has a fifty day moving average of GBX 1,494.88 and a 200 day moving average of GBX 1,448.56. Hikma Pharmaceuticals has a 52 week low of GBX 1,187 and a 52 week high of GBX 2,052. The company has a quick ratio of 1.27, a current ratio of 1.82 and a debt-to-equity ratio of 61.84.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.